Skip to main content

Table 1 Patient and operative characteristics

From: Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery

Patient characteristics

OLG group (n = 223)

Control group (n = 58)

P value

Mean age (range)

73.2 ± 10.7

73.9 ± 10.2

0.853

Gender

0.455

 M

133 (59.6%)

31 (53.4%)

 

 F

90 (40.4%)

27 (46.6%)

 

Mean BMI ± SD

22.1 ± 3.5

22.4 ± 3.7

0.6

Diabetes mellitus (%)

66 (29.6%)

19 (32.8%)

0.634

Alb

3.89 ± 0.52

3.86 ± 0.57

0.752

Respiratory disease

39 (17.5%)

8 (13.8%)

0.56

Anticoagulant

41 (16.7%)

10 (17.2%)

1

Primary lesion

1

 Stomach

66 (29.6%)

17 (29.3%)

 

 Colon

157 (70.4%)

41 (70.7%)

 

ASA

0.495

 1.2

171 (76.7%)

42 (72.4%)

 

 3

52 (23.3%)

16 (27.6%)

 

Mean operation time ± SD

303.0 ± 108.8

297.2 ± 134.9

0.732

Bleeding (ml)

130.4 ± 244.5

133.3 ± 152.8

0.932

Approach

0.000171

 Open

91 (43.8%)

42 (72.4%)

 

 Laparoscopy

117 (56.2%)

16 (27.6%)

 

 Transfusion

5 (2.3%)

1 (1.7%)

1

Stage

0.641

 0, I, II

150 (67.3%)

37 (63.8%)

 

 III, IV

73 (32.7%)

21 (36.2%)

 

Leakage

4 (1.8%)

5 (8.6%)

0.0205

Complication except SSI

51 (22.9%)

18 (31.0%)

0.232

Postoperative length of hospital stay (days)

15.8 ± 10.4

20.0 ± 15.8

0.0136

Adverse skin reaction (all)

4 (1.8%)

3 (5.2%)

0.157

 Skin irritation

2 (0.9%)

0 (0%)

1

 Erythema

3 (1.3%)

3 (5.2%)

0.105

 Pruritus

1 (0.4%)

1 (1.7%)

0.371

  1. Control group: PVP-I group